Acacia Pharma Issues Ordinary Shares to its Employee Benefit Trust
December 21, 2021 01:00 ET
|
Acacia Pharma Group plc
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. Publication in application of Article 15 of the Law of 2 May 2007 (the Transparency Law) Acacia Pharma Group plc As previously announced1, Acacia...
Correction: Issue of Shares to Employee Benefit Trust
December 16, 2021 06:18 ET
|
Acacia Pharma Group plc
Correction – Admission Date for New Ordinary Shares Included This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. ...
Issue of Shares to Employee Benefit Trust
December 16, 2021 01:00 ET
|
Acacia Pharma Group plc
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 16 December 2021: Acacia Pharma...
Acacia Pharma Announces Successful Completion of BARHEMSYS® Post-approval Requirement Study in Patients with Severe Renal Impairment
December 13, 2021 01:00 ET
|
Acacia Pharma Group plc
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 13 December 2021: Acacia Pharma...
Acacia Pharma to Present at the Jefferies London Healthcare Conference
November 10, 2021 07:00 ET
|
Acacia Pharma Group plc
Cambridge, UK and Indianapolis, US – 10 November 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), is pleased to announce that its Chief Executive...
Interim Results for the Six Months ended 30 June 2021 - Barhemsys® and Byfavo® Launches Continue to Achieve Strong Hospital Formulary Adoption
September 30, 2021 01:00 ET
|
Acacia Pharma Group plc
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Acacia Pharma Group plc Barhemsys® and Byfavo® launches continue...
Acacia Pharma Announces Submission and Validation of Marketing Authorization Application for BARHEMSYS® (amisulpride injection) in Major European Markets
September 29, 2021 01:00 ET
|
Acacia Pharma Group plc
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 29 September 2021: Acacia Pharma...
Correction: Notice of Results
September 23, 2021 07:10 ET
|
Acacia Pharma Group plc
Correction for date of KOL webcast Acacia Pharma to Report its Interim Results for the Six Months ended 30 June 2021 on 30 September 2021 Conference Call to be held on 30 September at 14.00...
Notice of Results
September 23, 2021 07:00 ET
|
Acacia Pharma Group plc
Acacia Pharma to Report its Interim Results for the Six Months ended 30 June 2021 on 30 September 2021 Conference Call to be held on 30 September at 14.00 CEST/08.00 EST Cambridge, UK and...
Acacia Pharma Announces Initiation of Pivotal Study of Byfavo® in Pediatric Procedural Sedation
September 16, 2021 01:00 ET
|
Acacia Pharma Group plc
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 16 September 2021: 07:00 CET Acacia...